DJO Announces Six-Month Free Access to the OaraScore Outpatient Risk Assessment Tool
DJO, a leading provider of medical technologies designed to get and keep people moving, announced today that OaraScore, DJO’s industry leading patient risk assessment algorithm, now will be available with a six-month free trial for all new users.
OaraScore is a software tool that provides medical professionals with the information needed to predict which patients are most medically appropriate for an outpatient total joint arthroplasty (TJA) procedure. This six-month free trial program will enable any surgeon, clinic or hospital to optimize patient selection, the most critical component of a successful outpatient TJA program.
“The recent healthcare crisis dramatically increases the need for elective surgeries to be done in an outpatient or same-day discharge basis, including total joint arthroplasty,” said Brady Shirley, CEO of DJO. “OaraScore is the most predictive, risk management tool designed specifically for total joint arthroplasty procedures to help ensure patients are cleared for outpatient surgery. It’s a clinically-proven tool that surgeons can seamlessly integrate into their practice and experience immediate patient safety benefits.”
The OaraScore utilizes a validated, multi-disciplinary algorithm that was featured in a peer-reviewed study published in The Journal of Arthroplasty in August 2017 by Dr. Michael Meneghini, director of the Indiana University Health Hip and Knee Center. The retrospective study, “Safe Selection of Outpatient Joint Arthroplasty Patients with Medical Risk Stratification: The ‘Outpatient Arthroplasty Risk Assessment Score,’” revealed a patient’s OaraScore for total joint replacement more precisely predicted the ability for the patient to discharge home the same day or the next morning than existing risk tools, such as ASA and CCI.1
“For the foreseeable future, it may be more realistic and appropriate for relatively healthy patients to avoid in-patient hospital stays, and it’s reassuring for surgeons to have a tool like OaraScore that can help safely transition many total joint arthroplasty patients into a more appropriate outpatient or same-day discharge pathway,” said Dr. Meneghini.
While several factors contribute to OaraScore’s superior greater predictive value1,2,3, a key differentiator is that OaraScore is the first patient risk stratification tool developed specifically for total joint replacement patients.
The clinical benefits of the OaraScore have been independently validated in an AAHKS podium presentation by Duke University researchers in 2016 and in an independent study by New York University Langone Medical Center (link) published in The Journal of Arthroplasty in August 2018.2,3
For more information, or to register for free trial access to the OaraScore, medical professionals are asked to visit: djoglobal.com/oarascore.
1. Meneghini, R. Michael, et al. “Safe selection of outpatient joint arthroplasty patients with medical risk stratification: the “outpatient arthroplasty risk assessment score”.” The Journal of arthroplasty 32, no. 8 (2017): 2325-2331.
2. Henderson, Robert, et al. “External Clinical Validation of the OARA Score for Outpatient Joint Arthroplasty Candidates”. Podium Presentation at AAHKS Meeting 2016, Paper #26.
3. Kelvin, Kim, et al. “Rapid Discharge in Total Hip Arthroplasty: Utility of the Outpatient Arthroplasty Risk Assessment Tool in Predicting Same-Day and Next-Day Discharge”. The Journal of Arthroplasty 33, (2018): 2412-2416.
Dr. R. Michael Meneghini is a paid consultant for DJO.
DJO, a subsidiary of Colfax Corporation (NYSE: CFX), is a leading developer and distributor of high-quality medical devices that provide proven solutions for musculoskeletal health, joint reconstruction, vascular health, and pain management. The Company’s extensive range of products and integrated technologies address the orthopedic continuum of care from performance and mobility to surgical intervention and post-operative rehabilitation; enabling people around the world to regain or maintain their natural motion. For additional information about DJO, please visit www.DJOGlobal.com.
Colfax Aktie jetzt ab 0€ handeln - auf Smartbroker.de